IQ-AI Limited Issue of Equity (2269O)
01 October 2019 - 4:00PM
UK Regulatory
TIDMIQAI
RNS Number : 2269O
IQ-AI Limited
01 October 2019
1 October 2019
IQ-AI Ltd
("IQ-AI" or the "Company")
Issue of Equity
IQ-AI is pleased to announce that due to demand from both new
and existing investors, Peterhouse Capital Limited has raised
GBP500,000 on behalf of the Company through the placing of
5,555,556 new ordinary shares (the "Placing Shares") at a price of
9.0 pence per Placing Share (the "Placing Price") (the
"Placing").
The Placing Price represents a 4% discount to the Volume
Weighted Average Price (VWAP) over the ten trading days prior to
completion of the Placing. The funds raised pursuant to the Placing
will be used for the Company's general working capital.
It is expected that the Placing Shares will commence trading at
8.00am on 7 October 2019.
Following completion of the Placing, the Company's issued share
capital will consist of 139,830,982 ordinary shares of 1 penny
each. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Duncan Vasey/Heena Karani
Tel: 020 7220 9797
About IQ-AI Ltd
IQ-AI, Ltd, the parent company of StoneChecker(R) and Imaging
Biometrics(R), is focused on advanced and state of the art medical
software and services. (IQ-AI.ltd). Imaging Biometrics develops and
provides visualization and analytical solutions that enable
clinicians to better diagnose and treat diseases with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent software plug-ins which can extend the base
functionality of workstations, imaging systems, PACS, or medical
viewers. By design, IB's advanced visualization software seamlessly
integrates into routine workflows.
Please visit www.imagingbiometrics.com for further
information.
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEWGUBUBUPBGQU
(END) Dow Jones Newswires
October 01, 2019 02:00 ET (06:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024